EMA Lapsed: Celdoxome pegylated liposomal (doxorubicin hydrochloride) — Baxter Holding B.V.

View source ↗

Summary

EMA notes that the marketing authorization for Celdoxome pegylated liposomal doxorubicin hydrochloride has lapsed, covering breast cancer, ovarian cancer, multi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Kaposi Sarcoma
• Multiple Myeloma
• Ovarian Cancer

Drugs mentioned

• Celdoxome pegylated liposomal doxorubicin hydrochloride (doxorubicin hydrochloride)

Snippet

Status: Lapsed. Therapeutic area: Breast Neoplasms;Ovarian Neoplasms;Multiple Myeloma;Sarcoma, Kaposi. MAH: Baxter Holding B.V.. Decision date: 21/03/2024